The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | A study comparing BR to ibrutinib in the frontline treatment of Waldenström’s macroglobulinemia
Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, presents findings from a study comparing fixed-duration bendamustine and rituximab (BR) with continuous ibrutinib in patients with Waldenström’s macroglobulinemia. The study revealed that while both treatments had similar progression-free survival (PFS) and overall survival (OS) rates, the BR group experienced deeper responses and a longer median time to the next therapy (TTNT). This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
